MarketPulse

cabozantinib

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kura Oncology's Darlifarnib-Cabozantinib Combo Shows Promise in Resistant Kidney Cancer

Kura Oncology reports darlifarnib plus cabozantinib achieved 44% response rate in cabozantinib-pretreated renal cell carcinoma patients, potentially overcoming drug resistance.
KURAclinical trial dataobjective response rate
The Motley FoolThe Motley Fool··James Halley

Exelixis Expands Beyond Cabozantinib With FDA Approval and Robust Pipeline

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.
MRKNTRAEXELFDA approvalbiotech